Please login to the form below

Not currently logged in
Email:
Password:

Priority Medicines

This page shows the latest Priority Medicines news and features for those working in and with pharma, biotech and healthcare.

Kite starts EU trial of lead CAR-T therapy

Kite starts EU trial of lead CAR-T therapy

Axi-cel has been granted an accelerated assessment by the EMA under its PRIME (priority medicines) initiative, which supports the development and speeds up the review of new therapies for areas

Latest news

  • Kite files first CAR-T candidate in Europe Kite files first CAR-T candidate in Europe

    Axicabtagene ciloleucel has been granted an accelerated assessment by the EMA under its PRIME (priority medicines) initiative, and Kite chief executive Arie Belldegrun said the EU filing "marks an important global

  • UK signals desire for close post-Brexit relationship with EU UK signals desire for close post-Brexit relationship with EU

    The UK government appears to be ready to take a more pragmatic stance on its post-Brexit approach to medicines regulation. ... ABPI chief executive Mike Thompson said: "This letter is a welcome recognition that the future of medicines regulation is a key

  • GSK tops Access to Medicines Index for fifth time running GSK tops Access to Medicines Index for fifth time running

    GSK tops Access to Medicines Index for fifth time running. Leads J&J and Novartis in 'needs-orientation' while Roche and Astellas lag. ... The Access to Medicines Index 2016. View the Access to Medicines Index 2016.

  • Ready for takeoff? Ready for takeoff?

    Priority Medicines, or PRIME, was launched by the European Medicines Agency (EMA) earlier this year in an effort to accelerate the medicine approval process in the European Union. ... It focuses on priority medicines, which are those that may be

  • PRIME Time in the EU PRIME Time in the EU

    Priority Medicines, or PRIME, is a programme launched by the European Medicines Agency (EMA) earlier this year in an effort to accelerate the medicine approval process in the European Union. ... It focuses on priority medicines, which are those that may

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • The real-world data conundrum The real-world data conundrum

    Regardless of what the actual total costs are, though, it is certain that, with very few exceptions, the era of blockbuster drugs is over and the demand for stratified medicines, affordable ... diseases. At a more fundamental level, though, availability

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    In the first quarter of 2016, the EMA launched a scheme for PRIority MEdicines (PRIME), to optimise development plans and provide accelerated assessment for medicines that are of major interest for ... In 2016 special approval pathways and designations

  • Market access improvements in Turkey Market access improvements in Turkey

    Almost the entire pharmaceutical market is made up of prescription medicines (93.8%) with 87% reimbursed. ... While welcoming the promise of a slight acceleration of review time with high priority medicines, industry is disappointed that orphan drugs and

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics